Literature DB >> 22343664

The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.

Marie-Anne Hospital, Alexa S Green, Catherine Lacombe, Patrick Mayeux, Didier Bouscary, Jerome Tamburini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22343664     DOI： 10.1182/blood-2011-11-393066

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors.

Authors:  Yong Xu; Benjamin G Brenning; Steven G Kultgen; Jason M Foulks; Adrianne Clifford; Shuping Lai; Ashley Chan; Shannon Merx; Michael V McCullar; Steven B Kanner; Koc-Kan Ho
Journal:  ACS Med Chem Lett       Date:  2014-10-22       Impact factor: 4.345

2.  Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.

Authors:  Lisa S Chen; Ji-Yeon Yang; Han Liang; Jorge E Cortes; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2016-04-07

3.  RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Authors:  M-A Hospital; A Jacquel; F Mazed; E Saland; C Larrue; J Mondesir; R Birsen; A S Green; M Lambert; P Sujobert; E-F Gautier; V Salnot; M Le Gall; J Decroocq; L Poulain; N Jacque; M Fontenay; O Kosmider; C Récher; P Auberger; P Mayeux; D Bouscary; J-E Sarry; J Tamburini
Journal:  Leukemia       Date:  2017-09-15       Impact factor: 11.528

Review 4.  PIM kinase (and Akt) biology and signaling in tumors.

Authors:  Noel A Warfel; Andrew S Kraft
Journal:  Pharmacol Ther       Date:  2015-03-05       Impact factor: 12.310

5.  Pim-1 kinase as cancer drug target: An update.

Authors:  Yernar Tursynbay; Jinfu Zhang; Zhi Li; Tursonjan Tokay; Zhaxybay Zhumadilov; Denglong Wu; Yingqiu Xie
Journal:  Biomed Rep       Date:  2015-12-24

6.  Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia.

Authors:  L L Yuan; A S Green; S Bertoli; F Grimal; V Mansat-De Mas; C Dozier; J Tamburini; C Récher; C Didier; S Manenti
Journal:  Leukemia       Date:  2013-06-10       Impact factor: 11.528

7.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Authors:  Erika K Keeton; Kristen McEachern; Keith S Dillman; Sangeetha Palakurthi; Yichen Cao; Michael R Grondine; Surinder Kaur; Suping Wang; Yuching Chen; Allan Wu; Minhui Shen; Francis D Gibbons; Michelle L Lamb; Xiaolan Zheng; Richard M Stone; Daniel J Deangelo; Leonidas C Platanias; Les A Dakin; Huawei Chen; Paul D Lyne; Dennis Huszar
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

8.  Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.

Authors:  Fabiola Cervantes-Gomez; Lisa S Chen; Robert Z Orlowski; Varsha Gandhi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-08-27

9.  Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication.

Authors:  Karthika Natarajan; Yingqiu Xie; Mehmet Burcu; Douglas E Linn; Yun Qiu; Maria R Baer
Journal:  PLoS One       Date:  2013-09-05       Impact factor: 3.240

Review 10.  Pim kinases in hematological malignancies: where are we now and where are we going?

Authors:  Patrizia Mondello; Salvatore Cuzzocrea; Michael Mian
Journal:  J Hematol Oncol       Date:  2014-12-10       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.